Tuesday, June 3, 2008

Immune Disease Institute and GlaxoSmithKline in $25M partnership

By Mass High Tech Staff

Immunoinflammation research has brought together pharmaceutical giant GlaxoSmithKline and Boston’s Immune Disease Institute.

The collaboration, a five-year effort worth $25 million, enables the institute and GlaxoSmithKline to draft joint grant proposals through the partnership’s alliance research grant program. The partnership will run through GlaxoSmithKline’s Immuno-Inflammation Centre of Excellence in Drug Discovery.

Under terms of the agreement, GlaxoSmithKline (NYSE:GSK) benefits by getting exclusive rights for IDI immunological developments, and IDI gains competitive strength from the pharmaceutical company in return.

The non-profit Immune Disease Institute, affiliated with Harvard Medical School, provides biomedical research associated with inflammation and immune defense.